Bio Updates Stocks Diva . Aeterna Zentaris Inc. (

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
Bio Updates Stocks Diva .



Aeterna Zentaris Inc. ( NASDAQ : AEZS) announced an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade®) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Based on the outcome of its pre-planned interim analysis of efficacy and safety, the DSMB recommended that patient enrollment be stopped and the study discontinued. The DSMB reported that it was highly unlikely the study would achieve a significant difference in its primary endpoint, progression free survival; no safety concerns were raised.

Juergen Engel, PhD, Aeterna Zentaris President and CEO stated, "We are obviously disappointed with the outcome of the interim analysis as reported to us by the DSMB, both from a patient and Company perspective. However, we remain focused on other significant opportunities such as our Phase 3 trial in endometrial cancer and Phase 2 trials in breast, prostate and bladder cancer with AEZS-108, our NDA filing for AEZS-130 as an oral diagnostic test for growth hormone deficiency in adults, as well as our earlier-stage oncology compound, AEZS-120."


ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced the initiation of a randomized, open label Phase 2 clinical study of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer.

The two-part, multi-center U.S. study will enroll up to 68 patients with non-resectable, recurrent or metastatic breast cancer who have visible lesions or lesions accessible by injection. The study is designed to assess the safety and efficacy of the drug combination of Ad-RTS IL-12 and palifosfamide. Ad-RTS IL-12 is a targeted and controlled DNA-based therapeutic designed to express interleukin-12 (IL-12), a protein important for an immune response to cancer. Palifosfamide is a potent bi-functional DNA alkylating agent.

Part one of the two-part study will consist of a safety assessment for Ad-RTS IL-12 and palifosfamide, alone or in combination. Part two will consist of an efficacy evaluation of the Ad-RTS IL-12 only arm and the combination arm. The primary endpoint of the study is rate of progression-free survival at 16 weeks. Secondary endpoints include objective response rate, duration of response and evaluation of pharmacodynamic tumor markers.

"Several recent breakthroughs in cancer treatment are based on the hypothesis that the immune system plays a central role in suppressing both cancer's growth and metastasis," said John Nemunaitis, M.D., lead investigator and Executive Medical Director, Mary Crowley Medical Research Center. "For breast cancer, the positive correlation of survival with immune response in the tumor elicited by non-immune treatments has only recently been elucidated, and this understanding hints at the potential for exciting new breakthroughs in this still underserved population. We look forward to participating in this study and to gaining further insight regarding the combined effect of Ad-RTS IL-12, a selectively controlled immunotherapy, and palifosfamide, a potent bi-functional DNA alkylating agent."

Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM, added, "This study has exciting potential, both for this difficult-to-treat indication and for our synthetic biology platform, in which Ad-RTS IL-12 is the lead program. Building on preclinical work supporting a synergistic effect between Ad-RTS IL-12 and palifosfamide, and the clinical findings from our ongoing Phase 2 melanoma study, we believe the combination of Ad-RTS IL-12 and palifosfamide has the potential to be quite impactful in breast cancer."

Abattis Bioceuticals Corp. (CNSX: FLU) (OTC: ATTBF), announces that it will not be proceeding with its $600,000 non-brokered private placement as previously announced in its Press Release dated February 12, 2013 as it is canvassing other avenues of financing through strategic relationships to prevent any dilution for its shareholders .

Abbott (NYSE: ABT) today announced positive long-term results for the company's innovative Absorb™ Bioresorbable Vascular Scaffold (BVS).

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade®) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Based on the outcome of its pre-planned interim analysis of efficacy and safety, the DSMB recommended that patient enrollment be stopped and the study discontinued.

Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2012 financial results after the market close on Thursday, March 21, 2013.

AmbiCom Holdings, Inc. (OTCQB: ABHI), a leading designer and developer of wireless products for the medical and automotive industries, and a distributor of innovative healthcare products, today announced for the second quarter ending January 31, 2013, a reported revenue of $785,717 with net income of $154,322 or $0.015 per share.

BioElectronics Corporation (OTC Pink: BIEL), the maker of unique inexpensive, patented, anti-inflammatory pain reliever devices announced that the OTC Bulletin, the leading global trade publication for over-the-counter healthcare products has chosen its ActiPatch® Musculoskeletal Pain Relief Therapy as the first runner-up for the "Most Innovative New OTC Product."

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Astellas Pharma Inc. (Tokyo: 4503) today announced that they entered into an agreement under which Cubist obtains the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas.

Edwards Lifesciences Corporation ( NYSE : EW), the global leader in the science of heart valves and hemodynamic monitoring, announced the three-year results of a pivotal clinical study of severe aortic stenosis patients at high-risk for surgery.

GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2012 and provided a business update.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 25th Annual ROTH Conference on March 18, 2013, at 3:00 p.m. PT (6:00 p.m. ET) in Laguna Nigel, CA.

Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious orphan lung diseases that are often life-threatening, today announced that the Company will release financial results for the three and twelve months ended December 31, 2012, before the opening of the stock market of Monday, March 18, 2013.

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held tomorrow, Tuesday, March 12, 2013 at 8:30 a.m. EDT to discuss the Company's fourth quarter and year-end 2012 financial results and provide a business outlook for 2013.

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2012.

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Adam H. Schechter, Executive Vice President and President, Global Human Health, Merck, has been appointed to its Board of Directors, effective April 1, 2013.

mPhase Technologies, Inc. (OTCBB: XDSL) announced today that it will be pursuing a broad array of government funding opportunities to collaborate with the U.S. Army for further development of its smart surface technology for products including reserve batteries and drug delivery systems and supercapacitors.

Micro Imaging Technology, Inc. (OTCQB: MMTC) announced that on March 7th the Travis County Texas District Court granted the Company's motion to dismiss a lawsuit filed by Alpine MIT Partners, LLC (Alpine) in May 2012.

Guy Sebastian, one of Australia's most well-known recording artists, today commented on a recent story in "The Australian" (www.mmrglobal.com/au) concerning the National E-Health Transition Authority (NEHTA), which has refused to respond to numerous requests from U.S. lawyers representing MMRGlobal, Inc. (OTCQB: MMRF) with regard to MMR's investigation of possible infringements of its Australian patents surrounding Personal Health Records ("PHRs").

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Roth Conference in Laguna Niguel.

SurgiCount Medical, Inc., the wholly owned operating subsidiary of Patient Safety Technologies, Inc. (OTCBB STX), today announced that Michael Roux has joined the Company in the position of Vice President of Product Management.

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company focused on developing first in class therapies for the treatment of cancer, announced today that its new Chief Executive Officer Dr. Peter Suzdak and Chief Financial Officer Ted Jeong are scheduled to make an investor presentation at ROTH Capital Partners’ 25th Annual ROTH Conference on Wednesday, March 20, at 12:30 pm Pacific Time.

Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB) announced today it has signed a material transfer agreement (MTA) with French-based VitamFero, a veterinary healthcare company. VitamFero, a member of Genopole®, will test Sirona Biochem's proprietary biological preservation technology with a goal to extend the storage time of its live attenuated animal vaccines.

SK3 Group, Inc. (OTC Pink: SKTO) today announces that it has acquired Medical Greens ™ and has changed its business model to focus purely in the medical marijuana space.

Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 18, 2013, at 9:00 a.m. EDT to provide a business update and discuss its fourth quarter and full year 2012 financial results.

VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces it will feature key developments involving CardioSafe 3D™, its pluripotent stem cell-based bioassay system for heart toxicity, in a poster presentation at the Society of Toxicology's 52nd Annual Meeting, the world's premier toxicology conference, in San Antonio, Texas, on March 11, 2013, at 7:30 am PDT.


Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Giovanni Recalde Sues County After False Report

Updated Category News Views 215

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 146

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 217

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 21

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 39

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 32

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 25

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 72

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 58

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 132

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

Estimating the Growth of $100 in Webster Financial Shares

Updated Category News Views 237

Understanding Webster Financial's Long-Term Growth Webster Financial, trading under the symbol WBS, has demonstrated a remarkable performance in the stock market over the past five years. The investment landscape can be unpredictable, but looking at WBS, we can observe that it has outperformed the market by an average of 3.91% annually, yielding a total annual return of...

Continue Reading
Grocery Outlet Shareholders Can Pursue Securities Fraud Claims

Updated Category News Views 129

Grocery Outlet Shareholders Can Pursue Securities Fraud Claims Investors have the chance to reclaim their losses after allegations of securities fraud at Grocery Outlet Holding Corp. (NASDAQ: GO). It’s crucial for all purchasers of Grocery Outlet securities who were active during the defined Class Period to understand their rights. Understanding the Class Period The...

Continue Reading
Core Bank Expands Services with New Banking Center Soon

Updated Category News Views 135

Core Bank Relocation to a New Overland Park Facility Core Bank is thrilled to announce its move to a new location for its Overland Park Banking Center. This relocation marks a significant milestone for the bank, allowing it to better serve the growing needs of the community. The modern banking space, set to open soon, is designed with improved accessibility and enhanced...

Continue Reading
Exploring Netflix's Recent Options Activity and Insights

Updated Category News Views 189

Netflix's Recent Options Trading Trends Financial giants have expressed a notable bullish sentiment toward Netflix. Analyzing the recent options trades for Netflix (NASDAQ: NFLX) reveals that 65 unusual trades have taken place, sparking considerable interest among investors. Traders' Sentiments and Volume Analysis Diving into the details, about 56% of traders exhibited...

Continue Reading
Simply Good Foods Faces Securities Fraud Lawsuit Turmoil

Updated Category News Views 53

Simply Good Foods: Murky Waters  Well, here we go again with yet another corporate mess. Simply Good Foods Company’s staring down a securities class action lawsuit over not-so-savory business moves that have knocked their stock into the gutter. The beef? Failing to spill the beans on troubles brewing from an acquisition that's gone south. Now, they’re facing a...

Continue Reading